Bayer’s Lampit Has Unique Status: US FDA’s Most ‘Critical’ Approval In 2020

Among the 53 new molecular entities cleared by FDA in 2020, Bayer’s Chagas disease therapy Lampit has a unique distinction: the approval required an in-person inspection that FDA actually conducted amid the COVID-related shutdown of routine pre-approval site visits.